Review
Nature Reviews Drug Discovery 5, 835-844 (October 2006) | doi:10.1038/nrd2130
There is a Corrigendum (1 February 2007) associated with this article.
Article series: Case Histories
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm1, Christopher Carter1, Mark Lynch1, Timothy Lowinger1, Jacques Dumas1, Roger A. Smith1, Brian Schwartz1, Ronit Simantov1 & Susan Kelley1 About the authors
Abstract
Since the molecular revolution of the 1980s, knowledge of the aetiology of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways. The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process. Here, we describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumour signalling and the tumour vasculature. The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) — from initial screening for a lead compound to FDA approval for the treatment of advanced renal cell carcinoma in December 2005 — was completed in just 11 years, with approval being received 
5 years after the initiation of the first Phase I trial.
- View At a Glance
Author affiliations
- Department of Cancer Research, Bayer Pharmaceuticals Corp., West Haven, Connecticut 06516, USA.
Correspondence to: Scott Wilhelm1 Email: scott.wilhelm.b@bayer.com
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
RESEARCH
The role of companion diagnostics in the development and use of mutation-targeted cancer therapiesNature Biotechnology Research (01 Aug 2006)
See all 11 matches for Research
